表紙
市場調查報告書

慢性骨髓性白血病(CML):開發中產品分析

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192527
出版日期 內容資訊 英文 598 Pages
訂單完成後即時交付
價格
慢性骨髓性白血病(CML):開發中產品分析 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 598 Pages
簡介

所謂慢性骨髓性白血病(CML)是指骨髓內部的造血細胞病變,並侵入血液的一種癌症。主要的風險因子有暴露在大量放射線下及年齡、性別等。主要症狀有疲勞感和倦怠感、盜汗、體重減輕,發熱,骨頭痛,脾臟肥大化,下腹部的疼痛和膨脹感等。主要的治療方法有放射線治療和造血細胞移植,化療等。

本報告提供全球各國治療慢性骨髓性白血病(CML)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

慢性骨髓性白血病(CML)概要

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12252IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the Chronic Myelocytic Leukemia (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 26, 22, 1, 15, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 4, 6 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Respiratory Syncytial Virus (RSV) Infections - Overview
  • Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development
  • Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
  • Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
  • Respiratory Syncytial Virus (RSV) Infections - Drug Profiles
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
  • Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
  • Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Arromax Pharmatech Co Ltd, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group International, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AstraZeneca Plc, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020